Brainsway Ltd Sponsored ADR Stock

$7.15

2.99% day before yesterday

Nasdaq, Sep 06, 10:00 pm CET

ISIN

US10501L1061

Symbol

BWAY

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Overview Dividends Analysts Charts News Strategies

Brainsway Ltd Sponsored ADR Stock price

$7.15

-3.22 31.06% 5Y

Nasdaq, Closing price Fri, Sep 06 2024

-0.22 2.99%

ISIN

US10501L1061

Symbol

BWAY

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Key metrics

Market capitalization	$119.25m
Enterprise Value	$75.48m
P/E (TTM) P/E ratio	195.89
EV/FCF (TTM) EV/FCF	12.95
EV/Sales (TTM) EV/Sales	2.07
P/S ratio (TTM) P/S ratio	3.27
P/B ratio (TTM) P/B ratio	2.77
Revenue growth (TTM) Revenue growth	42.00%
Revenue (TTM) Revenue	$36.43m
EBIT (operating result TTM) EBIT	$730.00k
Free Cash Flow (TTM) Free Cash Flow	$5.83m
Cash position	$48.14m
EPS (TTM) EPS	$0.04
P/E forward	negative
P/S forward	3.01
EV/Sales forward	1.91
Short interest	0.33%

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Brainsway Ltd Sponsored ADR Stock Analysis

Unlock Scores for Free

??

4 Analysts have issued a Brainsway Ltd Sponsored ADR forecast:

4x Buy

100%

More details on Analyst Estimates Including Price Targets

4 Analysts have issued a Brainsway Ltd Sponsored ADR forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Brainsway Ltd Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '24		+/- %
Revenue	36 36	42% 42% 100%
- Direct Costs	9.17 9.17	32% 32% 25%
Gross Profit	27 27	46% 46% 75%
- Selling and Administrative Expenses	19 19	19% 19% 52%
- Research and Development Expense	6.32 6.32	22% 22% 17%
EBITDA	2.02 2.02	116% 116% 6%
- Depreciation and Amortization	1.29 1.29	9% 9% 4%
EBIT (Operating Income) EBIT	0.73 0.73	105% 105% 2%
Net Profit	0.61 0.61	105% 105% 2%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Brainsway Ltd Sponsored ADR Stock News

Neutral

GlobeNewsWire

●

9 days ago

BrainsWay Appoints Richard A. Bermudes, M.D.

Dr. Bermudes is Widely Considered One of the Preeminent U.S. Clinicians in the TMS Field Dr. Bermudes is Widely Considered One of the Preeminent U.S. Clinicians in the TMS Field

Positive

Seeking Alpha

●

26 days ago

BrainsWay: Operating Leverage Driving Upside

BrainsWay reported strong earnings in Q2, with growth remaining strong and margins continuing to improve. Growth among enterprise accounts and internationally should ensure BrainsWay continues to perform well, provided that the macro environment remains stable. Neuronetics' decision to merge with Greenbrook TMS seems to support the strength of BrainsWay's business.

Neutral

Seeking Alpha

●

about one month ago

BrainsWay Ltd. (BWAY) Q2 2024 Earnings Call Transcript

BrainsWay Ltd. (NASDAQ:BWAY ) Q2 2024 Earnings Call Transcript August 6, 2024 8:30 AM ET Company Participants Brian Ritchie - IR, LifeSci Advisors Hadar Levy - CEO Ido Marom - CFO Conference Call Participants Steve Lichtman - Oppenheimer Jeffery S.

More Brainsway Ltd Sponsored ADR News

Company Profile

Brainsway Ltd. is a commercial stage medical device company, which focuses on the development and sale of non-invasive neuromodulation products using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The Deep TMS uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. The company was founded by Avner Hagai, Yiftach Roth, Abraham Zangen, and David Zacut on November 7, 2006 and is headquartered in Jerusalem, Israel.

Head office	Israel
CEO	Hadar Levy
Employees	106
Founded	2006
Website	www.brainsway.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now